AFP
CRSP icon

Ausdal Financial Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ausdal Financial Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Buy
4,862
+52
+1% +$2.74K 0.01% 881
2025
Q4 		$252K Sell
4,810
-309
-6% -$18.5K 0.01% 813
2025
Q3 		$332K Buy
+5,119
New +$294K 0.02% 691

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ausdal Financial Partners's CRSP Position: Q1 2026 in Review

Ausdal Financial Partners increased its CRISPR Therapeutics (CRSP) stake by 1.1% in Q1 2026, buying an estimated $2.74K and bringing the position to 4,862 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #881.

Ausdal Financial Partners first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. The position peaked at $332K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Ausdal Financial Partners held 4,862 shares of CRISPR Therapeutics worth $231K as of Q1 2026.
  • Ausdal Financial Partners bought 52 CRISPR Therapeutics shares in Q1 2026, an estimated $2.74K.
  • CRISPR Therapeutics made up 0.01% of Ausdal Financial Partners's portfolio in Q1 2026, its #881 holding.
  • Ausdal Financial Partners first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Ausdal Financial Partners's CRISPR Therapeutics position peaked at $332K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.